Federal Register Vol. 72, No[removed]Thursday, May 10, [removed]Notices Dated: May 4, 2007. Jeffrey Shuren, Assistant Commissioner for Policy. [FR Doc. E7–9056 Filed 5–9–07; 8:45 am] - Device register - Document - PDFSEARCH.IO

First Page		Document Content
Health Pharmaceutical industry Food and Drug Administration Pharmacology Drug safety Investigational New Drug Clinical trial Investigational Device Exemption Title 21 of the Code of Federal Regulations Research Clinical research Medicine		Federal Register / Vol. 72, No[removed]Thursday, May 10, [removed]Notices Dated: May 4, 2007. Jeffrey Shuren, Assistant Commissioner for Policy. [FR Doc. E7–9056 Filed 5–9–07; 8:45 am] Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 45,79 KB Share Document on Facebook

	Morphochem’s Investigational New Drug (IND) application accepted by FDA – Novel antibacterial for IV treatment of CDI ready to move to Phase 2 Munich (Germany), June 22, 2016 — Morphochem, a clinical-stage pharmace DocID: 1uvYN - View Document
	Guidance for Industry Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, DocID: 1sDEk - View Document
	Emergency Use: means the use of a test article on a human subject in a life-threatening situation in DocID: 1riMu - View Document
	Microsoft Word - 7494fnl.doc DocID: 1qYy2 - View Document
	Microsoft Worddoc DocID: 1qVAJ - View Document